PK measures in space and time: Summary of high-resolution methods

Dear All: 

I recently sent around discussions of ways to measure/estimate drug concentrations both in living animals (aptamer-based probes, Kevin Plaxco’s group) and with sufficient spatial resolution to permit construction of 2d/3d drug concentration maps (MALDI-MSI, David Perlin’s group).

In the context of our efforts to learn to better apply PK-PD (e.g., the 14-15 June 2017 NIAID PK-PD workshop), these notes generated a lot of interest and in particular Ed Weinstein (FDA) made me aware of a book chapter in which he and his co-authors had looked at a range of such techniques.

Finding this intriguing, I worked with Kevin, David, and Ed to prepare a summary of the range of current techniques for doing something that you could loosely call PK in high resolution by time and/or space. Several ways of categorizing the methods are shown in the table below and you’ll find more details on each in this downloadable summary document. It’s fascinating to see them side-by-side and realize the wealth of opportunities that exist.

Each approach has strengths and weaknesses but I must say that MALDI-MSI and aptamer-based probes really standout as exciting new tools by offering strong spatial information (MALDI-MSI) or easily obtained continuous drug measures (aptamer-based probes) based in both cases on measurements of the unmodified analyte

Overview of techniques: Specialized probe and/or modified analyte vs. general approach to detection of unmodified analytes

Continuous, with
potential for in vivo
Single* time point
Offers
spatial
resolution
Fluorescent probeHyperpolarized NMR/MRIPET ImagingPhotoacoustic imagingLow energy (3H or 14C) radio-labeled analyte
with Whole-Body AutoradiographyMALDI-MSILaser-capture microdissection
Single*
site
Aptamers on a probeMicrodialysisGrind tissue & assay extract

*Of course, any single time point or single site method could be extended by doing serial sampling but there are practical limits to how much of this you can do.

Rough rank order of spatial imaging resolution methods:

  1. Higher resolution: MALDI-MSI, autoradiography
  2. Lower resolution: Fluorescent probe, Hyperpolarized NMR/MRI, PET Imaging, Photoacoustic imaging, Laser-capture microdissection

Absolute analyte concentration data: (1) Aptamers on a probe, (2) Microdialysis (with difficulty), (3) Laser-capture microdissection, and (4) Grind tissue & assay extract

If this intrigues, you may also want to look both at this book and PK-specific chapter within it:

  1. Book: Imaging Infections : From Bench to Bedside. S. K. Jain.: https://link.springer.com/book/10.1007%2F978-3-319-54592-9
  2. Chapter in said book Ordonez, A. A., L. E. Bambarger, S. K. Jain and E. A. Weinstein (2017). Biodistribution and Pharmacokinetics of Antimicrobials. Imaging Infections : From Bench to Bedside. S. K. Jain. Cham, Springer International Publishing: 209-222. :https://link.springer.com/chapter/10.1007/978-3-319-54592-9_10

And to round out this summary of PK-related ideas, you might also want to review the material from

MANY thanks to Ed, David, and Kevin for provoking this interesting exploration!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

EPA (part 2, streptomycin!) / $104m ARPA-H AMR project

Dear All (OK, so now it’s 5 newsletters in as many days … exciting times … can’t keep up!), Two follow-up items today. First, yesterday’s newsletter about EPA’s concept note regarding AMR risks of pesticides prompted one of your fellow readers to remind me about this lawsuit filed with the U.S. Court of Appeals, Ninth Circuit: Case

BARDA Medical Countermeasures BAA: Substantial updates

Dear All (and yes, back-to-back newsletters … lots of action this week!): BARDA have today released a new version of their long-running BAA (Broad Agency Announcement, formerly BAA-18-100-SOL-00003) that seeks medical countermeasures (MCMs) for chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. The new BAA is BAA-23-100-SOL-00004 and has been completely reorganized and

Appropriate duration of antimicrobial dosing in food animal care

Dear All,  I’ve watched with interest the way that FDA’s CVM (Center for Veterinary Medicine) has been working steadily with the veterinary community as a whole to reduce antibiotic resistance pressure by improving the way antibiotics are used in animal care. The titles of these prior newsletters give you a feel for some aspects of

Scroll to Top